Role of MicroRNA in Endometrial Carcinoma

Zeeshan Javed, Mukhtar Ullah, Hafiz Ahsan Ashfaq, Afzaal Hussain Shah, Muhammad Shahzad, Muhammad Bilal, Aleena Sumrin, Hamid Bashir, Muhammad Hassan Siddiqi, Haleema Sadia

Abstract


Endometrial carcinoma (EC) is a hall mark of gynecological malignancies that usually affects women above the age 50. It is one of the major causes of mortality in females with ever increasing prevalence and the mortality rate is 1.7 to 2.4 per 100000 and each year 10000 death occur due to ECs. MiRNAs regulate the expression of different proto-oncogenes and signaling pathways that are directly or indirectly involved in the development of cancer. Different miRNAs i.e. (miRNA-449, miRNA 370, miRNA-424, and miRNA-152) which gets up or down regulated during endometrial cancer are the potential biomarkers for early diagnosis of EC. Targeting this relationship between the miRNA and signaling pathways may help in the development of new treatment in endometrial cancer. In current study, we reviewed literature from PubMed using miRNA and endometrial cancer as keywords and outlined the synthesis of potent miRNA and role of different miRNAs involved in ECs. The study revealed different sub types of miRNA played crucial role in the development of cancer by up and down regulation of different metabolic pathways. Many evidences have supported that miRNAs play role in control and regulation of different pathways leading to cancer and targeting these pathways may bring changes in the diagnosis as well as in treatment of EC.


Full Text:

PDF

References


Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. A Cancer Journal for Clinicians, (2016); 66(1): 7-30.

Tsikouras P, Bouchlariotou S, Vrachnis N, Dafopoulos A, Galazios G, et al. Endometrial cancer: molecular and therapeutic aspects. European Journal of Obstetrics & Gynecology and Reproductive Biology, (2013); 169(1): 1-9.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. A Cancer Journal for Clinicians, (2011); 61(2): 69-90.

Rose PG. Endometrial carcinoma. New England Journal of Medicine, (1996); 335(9): 640-649.

Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. Journal of the National Cancer Institute, (2000); 92(11): 924-930.

Leslie KK, Thiel KW, Goodheart MJ, De Geest K, Jia Y, et al. Endometrial cancer. Obstetrics & Gynecology Clinics of North America, (2012); 39(2): 255-268.

Cavanagh D, Fiorica JV, Hoffman MS, Durfee J, Nicosia SV. Adenocarcinoma of the Endometrium: An Institutional Review. Cancer Control, (1999); 6(4): 354-360.

Ryan AJ, Susil B, Jobling TW, Oehler MK. Endometrial cancer. Cell Tissue Research, (2005); 322(1): 53-61.

Zagouri F, Bozas G, Kafantari E, Tsiatas M, Nikitas N, et al. Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? Obstetrics and Gynecology International, (2010); 749579.

Secord AA, Havrilesky LJ, O'Malley DM, Bae-Jump V, Fleming ND, et al. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. Gynecologic Oncology (2009); 114(3): 442-447.

Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, (1993); 75(5): 843-854.

He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, et al. A microRNA polycistron as a potential human oncogene. Nature, (2005); 435(7043): 828-833.

Calin GA, Croce CM. MicroRNA signatures in human cancers. Nature Reviews Cancer, (2006); 6(11): 857-866.

Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. MicroRNA expression profiles classify human cancers. Nature, (2005); 435(7043): 834-838.

Thomson JM, Newman M, Parker JS, Morin-Kensicki EM, Wright T, et al. Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes & Development, (2006); 20(16): 2202-2207.

Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proceedings of National Academy of Sciences USA, (2008); 105(10): 3903-3908.

Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y, et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Science, (2005); 96(2): 111-115.

Lin RJ, Lin YC, Chen J, Kuo HH, Chen YY, et al. microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Research, (2010); 70(20): 7841-7850.

Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. New England Journal of Medicine, (2008); 359(25): 2641-2650.

Guo L, Zhang Y, Zhang L, Huang F, Li J, et al. MicroRNAs, TGF-beta signaling, and the inflammatory microenvironment in cancer. Tumor Biology, (2016); 37(1): 115-125.

Rakheja D, Chen KS, Liu Y, Shukla AA, Schmid V, et al. Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours. Nature Communications, (2014); 24802.

Wegert J, Ishaque N, Vardapour R, Georg C, Gu Z, et al. Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. Cancer Cell, (2015); 27(2): 298-311.

Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nature Reviews Genetics, (2008); 9(2): 102-114.

Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes & Development, (2003); 17(24): 3011-3016.

Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature, (2001); 409(6818): 363-366.

Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature, (2005); 436(7051): 740-744.

Lee HY, Doudna JA. TRBP alters human precursor microRNA processing in vitro. RNA, (2012); 18(11): 2012-2019.

Zhang L, Huang J, Yang N, Greshock J, Megraw MS, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proceedings of National Academy of Sciences USA, (2006); 103(24): 9136-9141.

Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of National Academy of Sciences USA, (2005); 102(39): 13944-13949.

Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Molecular Cell, (2007); 26(5): 731-743.

Jurcevic S, Olsson B, Klinga-Levan K. MicroRNA expression in human endometrial adenocarcinoma. Cancer Cell International, (2014); 14(1): 88.

Konno Y, Dong P, Xiong Y, Suzuki F, Lu J, et al. MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget, (2014); 5(15): 6049-6062.

Kaur S, Lotsari JE, Al-Sohaily S, Warusavitarne J, Kohonen-Corish MR, et al. Identification of subgroup-specific miRNA patterns by epigenetic profiling of sporadic and Lynch syndrome-associated colorectal and endometrial carcinoma. Clinical Epigenetics, (2015); 7(1): 20.

Banno K, Yanokura M, Iida M, Masuda K, Aoki D. Carcinogenic mechanisms of endometrial cancer: involvement of genetics and epigenetics. Journal of Obstetrics and Gynaecology Research, (2014); 40(8): 1957-1967.

Zhang G, Hou X, Li Y, Zhao M. MiR-205 inhibits cell apoptosis by targeting phosphatase and tensin homolog deleted on chromosome ten in endometrial cancer Ishikawa cells. BMC Cancer, (2014); 14: 440.

Zhang H, Wang X, Chen Z, Wang W. MicroRNA-424 suppresses estradiol-induced cell proliferation via targeting GPER in endometrial cancer cells. Cellular and Molecular Biology (Noisy-le-grand), (2015); 61(7): 96-101.

Gao Y, Liu T, Huang Y. MicroRNA-134 suppresses endometrial cancer stem cells by targeting POGLUT1 and Notch pathway proteins. FEBS Letters, (2015); 589(2): 207-214.

Jang SG, Yoo CW, Park SY, Kang S, Kim HK. Low expression of miR-449 in gynecologic clear cell carcinoma. International Journal of Gynecological Cancer, (2014); 24(9): 1558-1563.

Chen XP, Chen YG, Lan JY, Shen ZJ. MicroRNA-370 suppresses proliferation and promotes endometrioid ovarian cancer chemosensitivity to cDDP by negatively regulating ENG. Cancer Letters, (2014); 353(2): 201-210.

Ye W, Xue J, Zhang Q, Li F, Zhang W, et al. MiR-449a functions as a tumor suppressor in endometrial cancer by targeting CDC25A. Oncology Reports, (2014); 32(3): 1193-1199.




DOI: http://dx.doi.org/10.62940/als.v4i1.323

Refbacks

  • There are currently no refbacks.